Back to mobile site

Oppenheimer Reiterates Outperform Rating on MindMed (MNMD)

April 16, 2025 7:16 AM EDT Send to a Friend
Oppenheimer analyst Francois Brisebois reiterated an Outperform rating and $20.00 price target on MindMed (NASDAQ: MNMD).The analyst comments "MNMD announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login